Skip to content

Investigating the safety and efficacy of intra-arterial injection of bone marrow stem cells in patients with acute cerebral stroke

Investigating the safety and efficacy of intra-arterial injection of bone marrow stem cells compared to routine treatment in patients with acute cerebral stroke: in phase one and two of a randomized parallel clinical trial study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140818018842N49
Enrollment
48
Registered
2025-07-12
Start date
2025-07-23
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral stroke. G46.4

Interventions

Intervention 1: Intervention group: Upon arrival, patients with acute stroke symptoms undergo a brain CT scan. Then, based on the patients condition and symptoms, the initial CT scan imaging findings,

Sponsors

Motamed Cancer Institute
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Acute ischemic stroke in the MCA arterial territory NIHSS score =6 and <13 Absence of Large Vessel Occlusion (LVO) Thrombectomy not performed No improvement in symptoms related to the patient's recent acute stroke following relevant treatments except thrombectomy Absence of hemorrhage, either initially or following acute phase treatments

Exclusion criteria

Exclusion criteria: Known coagulation disorder or platelet dysfunction (but consumers of platelet inhibitors are allowed) Presence of Hemorrhage or Hemorrhagic Transformation at baseline or following treatment Hematological causes of stroke resulting from cell stasis. Liver failure Renal dysfunction with GFR below 30 Pregnant or breastfeeding patients Justifiable metabolic causes for Stroke-like symptoms Patients with evidence of life-threatening infections or life-threatening illness Presence of known cancer in the patient Positive HIV, HBV, HCV test Inability to tolerate MRI imaging required before the procedure

Design outcomes

Primary

MeasureTime frame
Primary and secondary outcomes: To evaluate the safety of the bleeding event, paraplegia, blindness, coma, decreased level of consciousness, and death are measured during and up to one year after the intervention. Timepoint: Measurements are taken at 3, 6 month, and 1 year intervals after the intervention. Method of measurement: To evaluate the effectiveness of infarct size, the NIHH, mRS, and Barthel indices.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Ghenaati

Tehran University of Medical Sciences

ghanaati@yahoo.com+98 21 6658 1577

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026